Wie hoch ist der Preis für Radiopharm Theranostics Limited (RAD)

Preis für Radiopharm Theranostics Limited (RAD) ist $0.00775813

Wie hoch ist die Marktkapitalisierung für Radiopharm Theranostics Limited (RAD)

Marktkapitalisierung für Radiopharm Theranostics Limited (RAD) ist $18.35M

Radiopharm Theranostics Limited (RAD) KBV

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.

Jahr	P/B-Verhältnis	ändert
Nicht genügend Daten für die angegebenen Daten.

Jahr

P/B-Verhältnis

ändert

Nicht genügend Daten für die angegebenen Daten.

Unternehmen	P/B-Verhältnis	P/B-Verhältnis-Differenz	Land
Vertex Pharmaceuticals Incorporated VRTX.US	6.3419	-	US
Argenx SE ARGX.US	6.2413	-	NL
CSL Limited CSL.AX	2.5054	-	AU
Lonza Group AG LONN.SW	-	-	CH
UCB S.A. UCB.BR	3.4612	-	BE

Unternehmen

P/B-Verhältnis

P/B-Verhältnis-Differenz

Land